Resminostat Maintenance Therapy Significantly Delays Disease Progression in Advanced Cutaneous T-Cell Lymphoma

Introduction: Addressing the Maintenance Gap in Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphomas (CTCL), specifically advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS), are rare and aggressive extranodal non-Hodgkin lymphomas. While various systemic therapies, including chemotherapy, biologics, and total skin electron beam (TSEB) therapy, can induce remission or disease control, these responses are often transient. The high relapse rate in advanced-stage disease poses a significant clinical challenge, as patients frequently cycle through multiple lines of treatment with diminishing returns. Until recently, there has been a lack of high-quality evidence supporting specific maintenance strategies to prolong disease control in this population. The RESMAIN trial, a multicentre, phase 2 randomized controlled study, sought to address this unmet need by evaluating the efficacy of resminostat, an oral histone deacetylase (HDAC) inhibitor, as a maintenance intervention.

Highlights of the RESMAIN Trial